Advertisement
Advertisement
NTLA
Intellia Therapeutics, Inc
12.31
USDSponsored
+0.45
+3.79%
Nov 04, 15:59 UTC -5
Closed
After-Market
12.31
0.00
-0.01%
Intellia Therapeutics, Inc (NTLA) Earnings
NTLA Earnings Reports
Positive Surprise Ratio
NTLA beat 24 of 42 last estimates.
57%
Next Report
Today
Date of Next Report
Nov 05, 2026
Estimate for Q3 26 (Revenue/ EPS)
$10.67M
/-$0.81
Implied change from Q2 26 (Revenue/ EPS)
+39.32%
/+1.25%
Implied change from Q3 25 (Revenue/ EPS)
-22.58%
/-11.96%
Intellia Therapeutics, Inc earnings per share and revenue
On Aug 06, 2026, NTLA reported earnings of -0.80 USD per share (EPS) for Q2 26, beating the estimate of -0.81 USD, resulting in a 1.86% surprise. Revenue reached 7.66 million, compared to an expected 14.18 million, with a -46.00% difference. The market reacted with a +2.46% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 13 analysts forecast an EPS of -0.81 USD, with revenue projected to reach 10.67 million USD, implying an increase of 1.25% EPS, and increase of 39.32% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
uniQure N.V.
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$0.94
Actual
-$0.88
Surprise
+6.39%
Nuvation Bio Inc.
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$0.12
Actual
-$0.12
Surprise
+4.15%
Cytek Biosciences, Inc. Common Stock
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$0.07
Actual
-$0.05
Surprise
+29.97%
Nuvectis Pharma, Inc. Common Stock
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$0.24
Actual
-$1.02
Surprise
-313.79%
Niagen Bioscience, Inc. Common Stock
Report Date
Nov 04, 2026 For Q3 26
Estimate
$0.00
Actual
-$0.01
Surprise
-263.93%
Revolution Medicines, Inc. Common Stock
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$2.46
Actual
-$1.90
Surprise
+22.81%
Cytokinetics Inc.
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$1.48
Actual
-$1.37
Surprise
+7.82%
Adaptive Biotechnologies Corporation Common Stock
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$0.09
Actual
$0.02
Surprise
+120.51%
Acadia Pharmaceuticals Inc.
Report Date
Nov 04, 2026 For Q3 26
Estimate
$0.20
Actual
$0.31
Surprise
+54.85%
Harmony Biosciences Holdings, Inc. Common Stock
Report Date
Nov 04, 2026 For Q3 26
Estimate
$1.15
Actual
$0.81
Surprise
-30.03%
FAQ
What were Intellia Therapeutics, Inc's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Intellia Therapeutics, Inc reported EPS of -$0.80, beating estimates by 1.86%, and revenue of $7.66M, -46% below expectations.
How did the market react to Intellia Therapeutics, Inc's Q2 2026 earnings?
The stock price moved up 2.46%, changed from $10.97 before the earnings release to $11.24 the day after.
When is Intellia Therapeutics, Inc expected to report next?
The next earning report is scheduled for Nov 05, 2026.
What are the forecasts for Intellia Therapeutics, Inc's next earnings report?
Based on 13
analysts, Intellia Therapeutics, Inc is expected to report EPS of -$0.81 and revenue of $10.67M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.